Can erythropoietin improve skeletal myoblast engraftment in infarcted myocardium?

Interactive Cardiovascular and Thoracic Surgery

Volumn 6, Issue 3, 2007, Pages 293-297

  Chanséaume, Sylvain ^a,b,c   Azarnoush, Kasra ^a,b,c   Maurel, Agnès ^a,b   Bellamy, Valérie ^a,b   Peyrard, Séverine ^d   Bruneval, Patrick ^a,d,e   Hagège, Albert A ^a,b,d,e   Menasché, Philippe ^a,b,d,e  

^a HÔPITAL BROUSSAIS   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Heart failure; Myoblasts; Myocardial infarction; Stem cells; Transplantation

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; ENGRAFTMENT; FEMALE; GRAFT SURVIVAL; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE PERFORMANCE; HEMATOCRIT; MALE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; CELL SURVIVAL; CELL TRANSPLANTATION; CELLS, CULTURED; ECHOCARDIOGRAPHY; ERYTHROPOIETIN; HEMATOCRIT; IN SITU NICK-END LABELING; MYOBLASTS; MYOCARDIAL INFARCTION; RATS; RATS, INBRED LEW; VENTRICULAR FUNCTION, LEFT;

EID: 34249778080     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1510/icvts.2006.144014     Document Type: Article

References (15)

1. Maurel A, Azarnoush K, Sabbah L, Vignier N, Le Lorc'h M, Mander C, Bissery A, Garcin I, Carrion C, Fiszman M, Bruneval P, Hagege A, Carpentier A, Vilquin JT, Menasche P. Can cold or heat shock improve skeletal myoblast engraftment in infarcted myocardium? Transplantation 2005;80:660-666.
2. Yau TM, Li G, Weisel RD, Reheman A, Jia ZQ, Mickle DA, Li RK. Vascular endothelial growth factor transgene expression in cell-transplanted hearts. J Thorac Cardiovasc Surg 2004;127:1180-1187.
3. Azarnoush K, Maurel A, Sabbah L, Carrion C, Bissery A, Mandet C, Pouly J, Bruneval P, Hagege AA, Menasche P. Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1-alpha. J Thorac Cardiovasc Surg 2005;130:173-179.
4. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. J Am Med Assoc 2005;293:90-95.
5. Ott HC, Bonaros N, Marksteiner R, Wolf D, Margreiter E, Schachner T, Laufer G, Hering S. Combined transplantation of skeletal myoblasts and bone marrow stem cells for myocardial repair in rats. Eur J Cardiothorac Surg 2004;25:627-634.
6. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-4806.
7. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003;100:11612-11617.
8. Van der Meer P, Lipsic E, Henning RH, Boddeus K, Van der Velden J, Voors AA, Van Veldhuisen DJ, Van Gilst WH, Schoemaker RG. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125-133.
9. Alghamdi AA, Albanna MJ, Guru V, Brister SJ. Does the use of erythropoietin reduce the risk of exposure to allogeneic blood transfusion in cardiac surgery? A systematic review and meta-analysis. J Card Surg 2006;21:320-326.
10. Depping R, Kawakami K, Ocker H, Wagner JM, Heringlake M, Noetzold A, Sievers HH, Wagner KF. Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 2005;130:877-878.
11. Hale SL, Sesti C, Kloner RA. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol 2005;46:211-215.
12. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
13. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rhim C, Martin H, Zeiher AM. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-1346.
14. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 2005;19:243-250.
15. Krause KT, Jaquet K, Geidel S, Schneider C, Mandel C, Stoll HP, Hertting K, Harle T, Kuck KH. Percutaneous endocardial injection of erythropoietin: assessment of cardioprotection by electromechanical mapping. Eur J Heart Fail 2006;8:443-450.